Known targets — ChEMBL curated mechanism
CSF1RFGFR1FGFR3FLT1FLT4ITKKDRKITLCKPDGFRAPDGFRB
The experimentally established mechanism targets of Pazopanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 15/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 10/20 | 0.98 |
| ▸ | PDGFRA known ✓ | P16234 | 9/20 | 0.98 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.98 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.98 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | FGFR1 known ✓ | P11362 | 2/20 | 0.98 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.98 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | AURKA | O14965 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pazopanib SCHEMBL29392503 | 0.99 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL588608 | 0.99 | KDR (1.00) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL159487 | 0.98 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL29386934 | 0.98 | KDR (0.98) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL935692 | 0.97 | KDR (0.97) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL3173301 | 0.97 | KDR (0.95) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025440 | 0.94 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025438 | 0.94 | KDR (0.90) | KDRKITPDGFRAFLT1FLT4 | |
| Pazopanib SCHEMBL13025441 | 0.93 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 | |
| SCHEMBL22720091 | 0.93 | KDR (0.89) | KDRKITPDGFRAFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181582-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | Qx Therapeutics Inc. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4149475-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | QX Therapeutics Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-11497747-B2 | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | Qx Therapeutics Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220202816-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | Qx Therapeutics Inc. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11304947-B2 | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | Qx Therapeutics Inc. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11497747-B2 | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | MAP3K3, MAP3K2, MAP3K13 | KDR 757/4885KIT 1895/4885PDGFRA 988/4885 |
| US-11304947-B2 | Compositions and methods for treating lung injuries associated with SARS-COV-2 infections | MAP3K3, MAP3K2, MAP3K13 | KDR 757/4885KIT 1895/4885PDGFRA 988/4885 |
| US-20220202816-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH SARS-COV-2 INFECTIONS | MAP3K3, MAP3K2, MAP3K13 | KDR 757/4885KIT 1895/4885PDGFRA 988/4885 |
| US-20230181582-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INJURIES ASSOCIATED WITH VIRAL INFECTIONS | MAP3K3, MAP3K2, MAP3K21 | KDR 1122/4885KIT 1509/4885PDGFRA 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.